Roche and Biogen Idec discontinue ocrelizumab for RA
This article was originally published in Scrip
Executive Summary
Roche and Biogen Idec have discontinued the Phase III development of their humanised anti-CD20 monoclonal antibody ocrelizumab for rheumatoid arthritis (RA) after deciding it has an unfavourable risk:benefit profile.
You may also be interested in...
P&G to co-promote Somaxon's Silenor in the US
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GSK's shingles vaccine begins Phase III studies
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
Optimer's fidaxomicin filing accepted in EU
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.